Twelve of twenty patients (60%) exhibited different levels of AR amplification and points to multiple temporal and spatial tumor clones in CTCs from patients with CRPC, that may be the result of selective pressures from treatment or evolution of the cancer as it progresses from hormone sensitive to CRPC. This evidence concerns the gene AR and cancer.